The Bioinformatics Shared Resource (BSR), supported by the Cancer Center Support Grant (CCSG) awarded to the Wistar Institute, collaborates with the vast majority of cancer center members on multiple research projects. My role as a Research Specialist and Managing Director of the BSR is to be engaged with all steps of many of those research programs. The institute-wide involvement in cancer-related studies allows me to develop comprehensive data analyses pipelines applicable across multiple programs, as well as to re-use obtained results, including databases, summarized and annotated datasets and other integrative resources, in carrying out analyses customized to particular studies. In combination with project-specific research efforts, which in turn also contribute to the existing knowledgebase, this integrative approach provides a robust scientific environment for applying methods of computational biology to various cancer-related studies as demonstrated in the application.

Public Health Relevance

The application is aimed to support cancer2related research efforts of The Wistar Institute investigators through computational expertise provided by Bioinformatics Shared Resource. Focus of the supported projects involve experiments on a number of cancer cell lines or primary cancers, including melanoma, ovarian, prostate, various blood cancers, lung, colon and many others. In a number of studies, genes within the project?s interest were shown to be clinically relevant in multiple cancers through analysis of clinically2relevant data and are shown to be deregulated in cancers, associated with metastasis, correlated with stage/grade/etc or significantly correlated with patient survival. There are also projects that focus on more basic mechanisms closely related to cancers: cell proliferation, apoptosis, invasion and motility, embryonic development, etc.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Project #
5R50CA211199-03
Application #
9537486
Study Section
Special Emphasis Panel (ZCA1)
Program Officer
Woodhouse, Elizabeth
Project Start
2016-09-15
Project End
2021-08-31
Budget Start
2018-09-01
Budget End
2019-08-31
Support Year
3
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Wistar Institute
Department
Type
DUNS #
075524595
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Echevarría-Vargas, Ileabett M; Reyes-Uribe, Patricia I; Guterres, Adam N et al. (2018) Co-targeting BET and MEK as salvage therapy for MAPK and checkpoint inhibitor-resistant melanoma. EMBO Mol Med 10:
Wu, Shuai; Fatkhutdinov, Nail; Fukumoto, Takeshi et al. (2018) SWI/SNF catalytic subunits' switch drives resistance to EZH2 inhibitors in ARID1A-mutated cells. Nat Commun 9:4116
Basu, Subhasree; Gnanapradeepan, Keerthana; Barnoud, Thibaut et al. (2018) Mutant p53 controls tumor metabolism and metastasis by regulating PGC-1?. Genes Dev 32:230-243
Karakashev, Sergey; Zhu, Hengrui; Wu, Shuai et al. (2018) CARM1-expressing ovarian cancer depends on the histone methyltransferase EZH2 activity. Nat Commun 9:631
Lu, Huimin; Bowler, Nicholas; Harshyne, Larry A et al. (2018) Exosomal ?v?6 integrin is required for monocyte M2 polarization in prostate cancer. Matrix Biol 70:20-35
Tso, For Yue; Kossenkov, Andrew V; Lidenge, Salum J et al. (2018) RNA-Seq of Kaposi's sarcoma reveals alterations in glucose and lipid metabolism. PLoS Pathog 14:e1006844
He, Yu-Mei; Li, Xing; Perego, Michela et al. (2018) Transitory presence of myeloid-derived suppressor cells in neonates is critical for control of inflammation. Nat Med 24:224-231
Fukumoto, Takeshi; Park, Pyoung Hwa; Wu, Shuai et al. (2018) Repurposing Pan-HDAC Inhibitors for ARID1A-Mutated Ovarian Cancer. Cell Rep 22:3393-3400
Lu, Fang; Wiedmer, Andreas; Martin, Kayla A et al. (2017) Coordinate Regulation of TET2 and EBNA2 Control DNA Methylation State of Latent Epstein-Barr Virus. J Virol :
Tikhmyanova, Nadezhda; Tutton, Steve; Martin, Kayla A et al. (2017) Small molecule perturbation of the CAND1-Cullin1-ubiquitin cycle stabilizes p53 and triggers Epstein-Barr virus reactivation. PLoS Pathog 13:e1006517

Showing the most recent 10 out of 31 publications